Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Scripts New Success in EMEA, Lifts Global Progress

by Zacks Equity Research

Align (ALGN) attains a significant milestone with accelerated adoption of Invisalign clear aligner therapy.

    Here's Why You Should Hold on to Becton, Dickinson Stock Now

    by Zacks Equity Research

    Becton, Dickinson (BDX) gains from strong fundamentals. Recent product recall issues raise concern.

      Patterson's (PDCO) NaVetor Launch to Boost Animal Health Unit

      by Zacks Equity Research

      Patterson Companies (PDCO) collaborates with Cure Partners to form a new business; launches NaVetor for Animal Health Unit.

        Integra LifeSciences Global Prospects Solid, Competition Rife

        by Zacks Equity Research

        Integra LifeSciences (IART) continues to expand overseas.

          Exelixis (EXEL) Jumps: Stock Rises 8%

          by Zacks Equity Research

          Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

            Pra Health Grows Organically, Symphony Synergies a Positive

            by Zacks Equity Research

            The $530-million Symphony buyout buoys hope for PRA Health (PRAH). The move is likely to improve its ability in the clinical research and commercial development process via data and analytics tools.

              Here's Why You Must Add STERIS (STE) to Your Portfolio Now

              by Zacks Equity Research

              STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.

                Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat

                by Zacks Equity Research

                Opko Health (OPK) gains from solid pharmaceutical business in the first quarter of 2018.

                  IDEXX Laboratories Global Growth Solid on Catalyst Uptake

                  by Zacks Equity Research

                  IDEXX (IDXX) steadily demonstrates strong organic growth, driven by solid sales at the Companion Animal Group (CAG) business, fueled by a firm global Catalyst uptake.

                    New Indication for Medtronic's Bone Cement Gets 510(K) Nod

                    by Zacks Equity Research

                    Medtronic (MDT) to broaden its commitment to the therapy of pathological fractures of the vertebral body on the back of its expanded indication for Kyphon HV-R Bone Cement.

                      Medtronic Gets Expanded FDA Nod for MiniMed 670G System

                      by Zacks Equity Research

                      Medtronic (MDT) continues to adopt initiatives to bolster the Diabetes segment.

                        Here's Why You Should Hold Merit Medical (MMSI) Stock Now

                        by Zacks Equity Research

                        Here we take a quick look at the major factors that plague Merit Medical (MMSI) and discuss the prospects that ensure near-term recovery.

                          Here's Why You Should Buy Integra LifeSciences (IART) Stock

                          by Zacks Equity Research

                          Integra LifeSciences' (IART) key developments on the overseas front buoy optimism on the stock among investors.

                            Why You Should Retain Quest Diagnostics in Your Portfolio

                            by Zacks Equity Research

                            Quest Diagnostics (DGX) reveals both sides of the same coin, reflecting its bleak aspects plaguing the stock as well as projecting its brighter side to denote a near-term rebound.

                              Here's Why You Should Hold AmerisourceBergen (ABC) Stock Now

                              by Zacks Equity Research

                              Here we discuss the primary factors that are plaguing AmerisourceBergen (ABC) and the prospects that indicate near-term recovery.

                                Patterson Companies' (PDCO) Earnings Meet Estimates in Q4

                                by Zacks Equity Research

                                Lackluster sales and earnings performance dampened Patterson Companies' (PDCO) fourth-quarter results.

                                  Paratek's Antibiotic Candidate Gets FDA Committee Date

                                  by Zacks Equity Research

                                  Paratek's (PRTK) NDA for its antibiotic candidate, omadacycline, to be reviewed by an FDA advisory committee on Aug 8.

                                    Here's Why You Should Steer Clear of Cerner (CERN) for Now

                                    by Zacks Equity Research

                                    Cerner's (CERN) downbeat view for 2018 and soft segmental performances fail to cheer investors.

                                      Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring

                                      by Zacks Equity Research

                                      Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.

                                        Array BioPharma (ARRY) Looks Good: Stock Adds 5.2% in Session

                                        by Zacks Equity Research

                                        Array BioPharma (ARRY) shares rose more than 5% in the last trading session, amid huge volumes.

                                          Here's Why You Should Hold Onto DENTSPLY SIRONA Stock Now

                                          by Zacks Equity Research

                                          DENTSPLY SIRONA (XRAY) gains from its increasing focus on innovation while a lowered earnings guidance for 2018 raises concern.

                                            Varian Medical's (VAR) ProBeam Platform Gains Foothold in UK

                                            by Zacks Equity Research

                                            Varian Medical's (VAR) ProBeam system is the first of its kind to deliver intensity-modulated proton therapy.

                                              Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

                                              by Zacks Equity Research

                                              Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

                                                REGENXBIO (RGNX) in Focus: Stock Moves 6.2% Higher

                                                by Zacks Equity Research

                                                REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

                                                  Here's Why You Must Add Surmodics (SRDX) to Your Portfolio

                                                  by Zacks Equity Research

                                                  Surmodics' (SRDX) efforts to improve research and development stature bode well.